AVA 017
Alternative Names: AVA-0017; AVA-017Latest Information Update: 28 Oct 2022
At a glance
- Originator Avacta
- Class Antineoplastics; Cystatins; Recombinant proteins
- Mechanism of Action CD223 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Cancer in United Kingdom
- 18 Sep 2018 AVA 017 is available for licensing as of 18 Sep 2018. https://www.avacta.com
- 18 Sep 2018 Avacta has patent protection for Affimer® technology in USA, Europe and Japan (Avacta website, September 2018)